**Table S1.** Clinical and demographic characteristics of the patient populations.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | PLWHART | PLWHEC | PLWHVP | HC | P |
| N | 19 | 19 | 19 | 19 |  |
| Age, years; median (IQR) | 55 (45-61) | 46 (40-52) | 46 (32-53) | 49 (46-52) | 0.027\* |
| Gender, Female; n (%) | 6 (31.6) | 9 (47.4%) | 7 (36.8) | 8 (42.1) | ns\*\* |
| Duration of treatment in years; Median (IQR)# | 17 (7-20) | - | - | - | - |
| Duration of suppressive therapy in years; Median (IQR) # | 13 (7-17) | - | - | - | - |
| Nadir CD4+ T-cell, cells/µl; median (IQR) | 280 (130-420) | 530 (400-680) | 280 (180-350) | - | <0.001\* |
| CD4+ T-cell, cells/µl; median (IQR) # | 576 (520-700) | 880 (730-1050) | 300 (180-410) | - | <0.001\* |
| CD8+ T-cell, cells/µl; median (IQR) # | 580(450-730) | 780(525-890) | 740(530-910) | - | ns |
| CD4:CD8 Ratio;median (IQR) # | 1.09 (0.71-1.45) | 1.30 (0.8-1.65) | 0.3 (0.2-0.6) | - | <0.001\* |
| Treatment Regimen; n (%) #ABC/3TC/DRVrABC/3TC/DTGABC/3TC/EFVABC/3TC/NVPABC/3TC/RPVDRV/COB/DTGRAL/3TC/EFVTDF/FTC/RPVTAF/FTC/DTGTAF/FTC/EFV | 1 (5.25)3 (15.8)2 (10.5)2 (10.5)3 (15.8)1 (5.25)1 (5.25)3 (15.8)2 (10.5)1 (5.25) | - | - | - | - |

\*Kruskal-Wallis, \*\*Chi square test, #At sampling